- CordenPharma Colorado has signed a 15-year lease for a 64,000-square-foot laboratory facility at BioMed Realty’s Flatiron Park campus in Boulder, Colorado.
- The facility will support peptide API process development and analytical services and will operate alongside the company’s existing manufacturing site.
CordenPharma Colorado has signed a 15-year lease for a 64,000-square-foot laboratory facility at BioMed Realty’s Flatiron Park campus in Boulder, Colorado. The new site at 5505 Central will house process development and analytical services supporting peptide active pharmaceutical ingredient (API) programs and will operate alongside the company’s existing large-scale peptide manufacturing facility.
The building is described as Boulder’s first purpose-built speculative laboratory facility. The LEED® Gold-certified space includes power capacity, adaptable laboratory grids, advanced mechanical and utility systems, and waste-handling infrastructure designed for scientific operations. The company plans to use the site to support peptide drug substance development and contract manufacturing activities.
The location sits within BioMed Realty’s Flatiron Park campus, which hosts tenants from the life sciences, quantum technology, and broader innovation sectors. CordenPharma Colorado will be the sole tenant at the facility. The development laboratories are intended to enable integration of peptide API development with manufacturing, supporting programs from early process development through commercial production.
“We’re excited to partner with BioMed Realty on this project to accelerate our strategic growth and meet customer demand for complex peptide outsourcing, while creating additional jobs and attracting research talent to the region.”
Michael Landau, Managing Director of CordenPharma Colorado
The expanded peptide development capabilities created at the Boulder location will also connect with CordenPharma’s global network of facilities across Europe and the United States, supporting customers seeking CDMO and contract manufacturing services for peptide drug substance programs.
